Galapagos NV (AMS:GLPG) stock most popular amongst retail investors who own 56%, while public companies hold 25%

Bron: Yahoo Entertainment

Gepubliceerd op: 2024-12-13

Brokerages Set Galapagos NV (NASDAQ:GLPG) Target Price at $30.75

Bron: ETF Daily News

Autheur: MarketBeat News

Gepubliceerd op: 2024-11-27

Galapagos NV (NASDAQ:GLPG – Get Free Report) has been assigned an average recommendation of “Reduce” from the seven analysts that are presently covering the company, Marketbeat Ratings reports. Two equities research analysts have rated the stock with a sell r…

Galapagos NV (NASDAQ:GLPG) Stake Lowered by Fmr LLC

Bron: ETF Daily News

Autheur: MarketBeat News

Gepubliceerd op: 2024-12-08

Fmr LLC decreased its stake in Galapagos NV (NASDAQ:GLPG – Free Report) by 44.6% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 1,598,912 shares of the biotechnology c…

Leerink Partnrs Forecasts Stronger Earnings for Galapagos

Bron: ETF Daily News

Autheur: MarketBeat News

Gepubliceerd op: 2024-12-12

Galapagos NV (NASDAQ:GLPG – Free Report) – Analysts at Leerink Partnrs lifted their FY2024 earnings per share estimates for shares of Galapagos in a note issued to investors on Sunday, December 8th. Leerink Partnrs analyst F. Khurshid now forecasts that the b…

Galapagos (NASDAQ:GLPG) Cut to “Reduce” at Kepler Capital Markets

Bron: ETF Daily News

Autheur: MarketBeat News

Gepubliceerd op: 2024-11-22

Galapagos (NASDAQ:GLPG – Get Free Report) was downgraded by equities researchers at Kepler Capital Markets from a “hold” rating to a “reduce” rating in a research report issued on Wednesday, MarketBeat.com reports. Several other analysts have also commented o…

Galapagos Announces Encouraging New Results from Ongoing Phase 1/2 Study of CD19 CAR T-Cell Therapy, GLPG5101, in Patients with Relapsed/Refractory Non-Hodgkin Lymphoma

Bron: GlobeNewswire

Autheur: Galapagos NV

Gepubliceerd op: 2024-12-07

Mechelen, Belgium; December 7, 2024, 18:30 CET; Galapagos NV (Euronext & NASDAQ: GLPG) today announced additional data from the ongoing Phase 1/2 ATALANTA-1 study of its CD19 CAR T-cell therapy, GLPG5101. The results, featured in an oral presentation at the 6…

Belgium stocks higher at close of trade; BEL 20 up 0.50%

Bron: Investing.com

Autheur: Investing.com

Gepubliceerd op: 2024-11-20

Belgium stocks higher at close of trade; BEL 20 up 0.50%

Galapagos kondigt bemoedigende nieuwe resultaten aan van de lopende fase 1/2-studie van de CD19 CAR T-celtherapie GLPG5101 bij patiënten met recidief/refractair non-Hodgkin lymfoom

Bron: GlobeNewswire

Autheur: Galapagos NV

Gepubliceerd op: 2024-12-07

Mechelen, België; 7 december 2024, 18:30 CET; Galapagos NV (Euronext & NASDAQ: GLPG) kondigde vandaag bijkomende resultaten aan van de lopende fase 1/2 ATALANTA-1 studie van zijn CD19 CAR T-celtherapie, GLPG5101. De resultaten, gepresenteerd tijdens een monde…

Reviewing Gilead Sciences (NASDAQ:GILD) & Cardiol Therapeutics (NASDAQ:CRDL)

Bron: ETF Daily News

Autheur: MarketBeat News

Gepubliceerd op: 2024-11-25

Gilead Sciences (NASDAQ:GILD – Get Free Report) and Cardiol Therapeutics (NASDAQ:CRDL – Get Free Report) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownershi…